Difference between revisions of "Dapsone"
Neil.m.young (talk | contribs) (Text replacement - "Toxoplasmosis " to "Toxoplasmosis ") |
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Hansen disease (leprosy) | *Hansen disease (leprosy) | ||
| − | **paucibacillary: | + | **paucibacillary: 100mg PO qd x6mo |
***Use with rifampin | ***Use with rifampin | ||
| − | **multibacillary: | + | **multibacillary: 100mg PO qd x12mo |
***Use with rifampin, clofazimine | ***Use with rifampin, clofazimine | ||
| − | *Dermatitis herpetiformis: | + | *Dermatitis herpetiformis: 50mg PO qd |
| − | *PCP prophylaxis: | + | *PCP prophylaxis: 100mg/day PO divided qd-bid |
**Off label use | **Off label use | ||
| − | *PCP tx: | + | *PCP tx: 100mg PO qd x21 days |
**Not 1st-line agent; use with trimethoprim | **Not 1st-line agent; use with trimethoprim | ||
**Off label use | **Off label use | ||
| − | *Malaria suppression: | + | *Malaria suppression: 100mg PO qwk |
**Use with pyrimethamine | **Use with pyrimethamine | ||
**Off label use | **Off label use | ||
| − | *[[Toxoplasmosis]] prophylaxis: | + | *[[Toxoplasmosis]] prophylaxis: 50mg PO qd |
**Off label use | **Off label use | ||
Revision as of 11:25, 21 July 2016
Contents
Administration
- Type: Antibiotic
- Dosage Forms: 25,100
- Routes of Administration: Oral
Adult Dosing
- Hansen disease (leprosy)
- paucibacillary: 100mg PO qd x6mo
- Use with rifampin
- multibacillary: 100mg PO qd x12mo
- Use with rifampin, clofazimine
- paucibacillary: 100mg PO qd x6mo
- Dermatitis herpetiformis: 50mg PO qd
- PCP prophylaxis: 100mg/day PO divided qd-bid
- Off label use
- PCP tx: 100mg PO qd x21 days
- Not 1st-line agent; use with trimethoprim
- Off label use
- Malaria suppression: 100mg PO qwk
- Use with pyrimethamine
- Off label use
- Toxoplasmosis prophylaxis: 50mg PO qd
- Off label use
Pediatric Dosing
Special Populations
- Pregnancy Rating: C
- Lactation risk: Probably unsafe
Renal Dosing
- No adjustment
Hepatic Dosing
- Caution advised with hepatic impairment
- CBC qwk x4, qmo x6, then q6mo thereafter
- LFTs at baseline, then periodically
Contraindications
- Allergy to class/drug
- caution if renal or hepatic impairment
- caution if impaired cardiovascular function
Adverse Reactions
Serious
- anemia, hemolytic
- aplastic anemia
- agranulocytosis
- exfoliative dermatitis
- erythema multiforme
- toxic epidermal necrolysis
Common
- fever
- myalgia
- headache
- rigors
- fatigue
- malaise
- dizziness
Pharmacology
- Half-life: 28 hrs
- Metabolism: Liver, CYP450
- Excretion: Urine